ID
ICPT

Integral Derivatives’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Integral Derivatives’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,000
Closed -$1.09M – 1425
2016
Q4 		$1.09M Buy
10,000
+4,000
+67% +$477K 0.02% 486
2016
Q3 		$988K Sell
6,000
-2,900
-33% -$457K 0.02% 439
2016
Q2 		$1.27M Buy
+8,900
New +$1.3M 0.03% 345
2016
Q1 		– Sell
-2,100
Closed -$314K – 1155
2015
Q4 		$314K Sell
2,100
-100
-5% -$16.9K 0.01% 796
2015
Q3 		$365K Buy
2,200
+1,100
+100% +$242K 0.01% 800
2015
Q2 		$266K Buy
+1,100
New +$293K 0.01% 904
2015
Q1 		– Sell
-2,500
Closed -$390K – 1450
2014
Q4 		$390K Buy
+2,500
New +$462K 0.01% 993

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Integral Derivatives's ICPT Position: Q2 2015 in Review

Integral Derivatives sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2015, closing a stake of 758 shares — an estimated $202K sold.

Integral Derivatives first reported a position in ICPT in Q1 2014 and held it in 3 quarters. The position peaked at $2.28M in Q2 2014. 191 funds tracked by Wall St. Rank hold ICPT as of Q2 2015.

  • Integral Derivatives reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Integral Derivatives sold 758 Intercept Pharmaceuticals, Inc. shares in Q2 2015, an estimated $202K.
  • Integral Derivatives first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 3 quarters.
  • Integral Derivatives's Intercept Pharmaceuticals, Inc. position peaked at $2.28M in Q2 2014.
  • 191 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2015.

Based on Integral Derivatives's 13F filing for Q2 2015, filed 15 Jul 2015.